Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.71 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999042 | 0.83 | QPCT (1.00) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL16384621 | 0.83 | QPCT (0.66) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17483161 | 0.83 | QPCT (0.75) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL21858082 | 0.83 | QPCT (0.75) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL2755863 | 0.81 | QPCT (0.73) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17481127 | 0.81 | CYP3A4 (0.74) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL13033264 | 0.81 | QPCT (0.71) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL17481128 | 0.80 | CYP3A4 (0.82) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL2755855 | 0.80 | QPCT (0.71) | QPCTQPCTLCYP3A4CYP2D6TSHR | |
| SCHEMBL7567011 | 0.80 | QPCT (0.71) | QPCTQPCTLCYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383813-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671064-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169802-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2005063763-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152196-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | QPCT 24/4885QPCTL 522/4885CYP3A4 42/4885 |
| US-20120004253-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | QPCT 24/4885QPCTL 522/4885CYP3A4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.